I.Yu. VIZEL, A.A. VIZEL, N.B. AMIROV

Kazan State Medical University, 49 Butlerov Str., Kazan, Russian Federation, 420012

Vizel I.Yu. ― Cand. Med. Sc., Assistant of the Department of Phthisiopulmonology, tel. +7-903-388-71-64, e-mail: tatpulmo@mail.ru

Vizel A.A. ― D. Med. Sc., Professor, Head of the Department of Phthisiopulmonology, tel. +7-987-296-25-99, e-mail: lordara@inbox.ru

Amirov N.B. ― D. Med. Sc., Professor of the Department of General Medical Practice, tel. +7-905-313-01-11, e-mail: namirov@mail.ru

Clinical and spirometric examination of 87 patients with chronic obstructive pulmonary disease (COPD) with an interval of 1 year was conducted. The proportion of COPD patients with peripheral blood eosinophilia in the studied group of patients was 19.9%. During the first year of observation significant improvement occurred in patients with blood eosinophilia treated with inhalant glucocorticosteroids (iGCS) ― by 17.9%, while among COPD patients with eosinophilia and FEV1 <50% of predicted ― by 26.3%. Among COPD patients with eosinophilia dynamics of FEV1 had a high direct linear dependance of the dose of iGCS (r=0,710), despite the small size sample. With the selected subgroup without eosinophilia the correlation is reversed (r=-0,253). The high degree of conjugation baseline FEV1 below 50% and above with the followed dynamics within 1 year was in COPD patients with peripheral blood eosinophilia (chi-square=7,48; d.f.=1; p=0,006). This conjugation was also accurate in patients with eosinophilia who have not been receiving iGCS (chi-square=4,17; d.f.=1; p=0,04). Peripheral blood eosinophilia is an independent of the therapy positive prognostic indicator in relation to the dynamics of FEV1 within 1 year. In COPD patients with eosinophilia and especially at lower FEV1 less than 50% of the normal value is established positive effect of inhaled corticosteroids on FEV1. The amount of patients with COPD and peripheral blood eosinophilia does not exceed 20%, which makes it prudent to apply iGCS in patients with this nosology strictly for the existing indications.

Key words: chronic obstructive pulmonary disease (COPD), forced expiratory volume1, eosinophilia, inhaled glucocorticosteroids.

REFERENCES

1. Duncan D. Chronic obstructive pulmonary disease: an overview. Br. J. Nurs, 2016, 25 (7), pp. 360-366.
2. Vizel’ A.A., Vizel’ I.Yu., Amirov N.B. Chronic obstructive pulmonary disease (COPD). Changes as a cause for discussion. Vestnik sovremennoy klinicheskoy meditsiny, 2015, vol. VIII, iss. 1, pp. 62-69 (in Russ.).
3. Pronina E.Yu. The top of the iceberg: the epidemiology of COPD (literature review). Vestnik sovremennoy klinicheskoy meditsiny, 2011, vol. IVI, iss. 3, pp. 18-32 (in Russ.).
4. Vafin A.Yu., Vizel’ A.A., Sherputovskiy V.G. et al. Sherputovsky and other respiratory diseases in the Republic of Tatarstan:. long-term epidemiological analysis. Vestnik sovremennoy klinicheskoy meditsiny, 2016, vol. 9, no. 1, pp. 24-31 (in Russ.).
5. Baloira V.A., Pallarés S.A. Chronic obstructive pulmonary disease with eosinophilia, an Emerging Phenotype? Arch. Bronconeumol, 2016, 52 (4), pp. 177-178.
6. Miravitlles M., Vogelmeier C., Roche N. et al. A review of national guidelines for management of COPD in Europe. Eur. Respir. J, 2016, 47 (2), P. 625-637.
7. Vizel’ I.Yu. Izmenenie vneshnego dykhaniya u bol’nykh KhOBL (rezul’taty dlitel’nogo nablyudeniya): avtoref. dis. … kand. med. nauk [Changing the appearance of breathing in COPD patients (results of long-term follow-up). Synopsis of dis. PhD med. sciences]. Moscow, 2009. 27 p.
8. Shmelev E.I., Vizel’ I.Yu., Vizel’ A.A. Change in forced expiratory spirometry parameters in COPD patients (results of long-term monitoring). Tuberkulez i bolezni legkikh, 2010, no. 8, pp. 50-56 (in Russ.).
9. Serafino-Agrusa L., Scichilone N., Spatafora M., Battaglia S. Blood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: A case-control study. Pulm. Pharmacol. Ther, 2016, 37, pp. 89-94.
10. Park H.Y., Lee H., Koh W.J. et al. Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis, 2015, Dec 22, 11, pp. 23-30.